CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lupin Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lupin Ltd
3rd Floor,
Kalpataru Inspire,, Off. Western Express
Phone: +91 2266402323p:+91 2266402323 MUMBAI, 400055  India Ticker: LUPINLUPIN
Business Summary
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. The Company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (API). It operates predominantly in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The Company has a presence in the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments and also operates in the anti-TB and cephalosporins segments. Its generic formulations include Filgrastim, Pegfilgrastim, Etanercept and Albuterol, among others. Its diabetes brands include ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol, and NeuroVance, among others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Manju D.Gupta 78 8/11/2017 1/1/2011
Chief Executive Officer, Executive Director Vinita D.Gupta 56 9/1/2013 9/1/2013
Executive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU RameshSwaminathan 57 1/1/2024 8/13/2007
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Lupin Pharmaceuticals, Inc. Harborplace Tower Baltimore MD United States
Symbiomix Therapeutics, LLC 105 Lock Street Newark NJ United States
GAVIS Pharmaceuticals LLC 400 Campus Drive Somerset NJ United States
Novel Laboratories, Inc. 400 Campus Drive Somerset NJ United States

Business Names
Business Name
500257
EQLUPIN
GAVIS Pharmaceuticals LLC
13 additional Business Names available in full report.

General Information
Number of Employees: 21,868 (As of 3/31/2024)
Outstanding Shares: 456,197,563 (As of 11/19/2024)
Shareholders: 286,705
Stock Exchange: NSE
Fax Number: +91 2266402051


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024